Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance
Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.
You may also be interested in...
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
After clinching massive licensing-out agreements with multinationals last year, Yuhan is setting out a long-term global road map with a determination that it won’t just remain top in the South Korean market. The head of the firm's newly established global strategy department talks to Scrip how and why it aims to achieve globalization in the next decade and beyond.